| 词条 | Atazanavir/cobicistat |
| 释义 |
| drug_name = | type = combo | component1 = Atazanavir | class1 = HIV protease inhibitor | component2 = Cobicistat | class2 = Cytochrome P450 (CYP3A) inhibitor | pronounce = | tradename = Evotaz | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_UK = | legal_US = | legal_UN = | legal_NZ = | legal_status = | routes_of_administration = | CAS_number = | ATCvet = | ATC_prefix = | ATC_suffix = | PubChem = | DrugBank = }} Atazanavir/cobicistat (trade name Evotaz) is an antiretroviral medication used to treat and prevent HIV/AIDS. It is a fixed dose combination drug containing 300 mg of atazanavir and 150 mg of cobicistat.[1] Atazanavir is an HIV protease inhibitor and cobicistat blocks the body's metabolism of atazanavir by the enzyme CYP3A prolonging its effectiveness. It was approved by the Food and Drug Administration for use in United States in 2015.[2] References1. ^{{cite web | url = https://packageinserts.bms.com/pi/pi_evotaz.pdf | title = Evotaz Packing Insert }} {{HIVpharm}}2. ^{{Cite press release | title = U.S. Food and Drug Administration Approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults | url = https://news.bms.com/press-release/financial-news/us-food-and-drug-administration-approves-bristol-myers-squibbs-evotaz-a | publisher = Bristol-Myers Squibb}} 2 : Antiretroviral drugs|Combination drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。